文献速递心外重症与机械循环支持

心脏外科术后继发性硬化性胆管炎:预后不良的并发症

Secondary sclerosing cholangitis in cardiac surgical patients: A complication with a dismal prognosis.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-04-27

该回顾性研究纳入2007年至2016年8625例成人心脏手术患者,发现12例(0.14%)发生危重患者继发性硬化性胆管炎,并与匹配对照组比较。结果显示该组患者血管活性药物和呼吸支持时间更长、手术翻修更多、胆红素和肝酶更高,病死率高达92%(对照组33%)。

要点

  • 心脏术后继发性硬化性胆管炎发生率约0.14%,病死率高达92%。
  • 术后病程复杂、长期使用血管活性药物和呼吸支持、多次手术翻修者需警惕。
  • 肝移植是唯一治愈手段,但常因年龄和危重状态受限。

核心结论

  • 危重患者继发性硬化性胆管炎是心脏手术后的致命并发症,发生于术后病程复杂、需要长时间血管活性药物和呼吸治疗或频繁手术翻修的患者。
  • 肝移植仍是唯一治愈选择,但常因心脏手术患者的年龄和危重状态而无法进行。

研究设计与样本

  • 回顾性研究,检索2007年4月至2016年3月期间所有接受心脏手术的成年患者(18-93岁)中诊断为继发性硬化性胆管炎和/或肝衰竭者,8625例中识别192例,其中12例诊断为危重患者硬化性胆管炎(发生率0.14%)。
  • 采用3:1匹配,从医院数据库提取实验室值、药物需求、通气时间、机械循环支持和内镜逆行胰胆管造影研究。

主要发现

  • 共9男3女受累,年龄71岁(范围59.8-75.5岁)。

临床怎么用

  • 心脏术后出现黄疸或肝功能异常且病程复杂、长期使用血管活性药物和呼吸支持者,应警惕继发性硬化性胆管炎。
  • 对于频繁手术翻修和长期重症监护的患者,需监测胆红素、γ-谷氨酰转移酶和碱性磷酸酶等指标。
  • 确诊后应评估肝移植可能性,但需考虑患者年龄和危重状态对移植可行性的限制。

局限性

  • 回顾性单中心研究,样本量小(12例患者),可能存在选择偏倚和信息偏倚。
  • 匹配对照组仅来自同一数据库,未能完全控制所有混杂因素。
  • 研究期间跨度较长,治疗策略可能发生变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Secondary sclerosing cholangitis in critically ill patients is a rapidly progressing disease leading to biliary fibrosis and cirrhosis. We describe the course of sclerosing cholangitis in critically ill patients after cardiac surgery and compare this with matched patients. METHODS: A retrospective search for "secondary sclerosing cholangitis" and "liver and/or hepatic failure" in all adult patients (aged 18-93 years) who underwent cardiac surgery from April 2007 to March 2016 identified 192 of 8625 patients. Of those, 12 were diagnosed with sclerosing cholangitis in critically ill patients (incidence, 0.14%). A 3:1 matching was performed. Laboratory values, pharmacologic requirements, ventilation times, mechanical circulatory support, and endoscopic retrograde cholangiopancreatography studies were extracted from the hospital database. RESULTS: A total of 9 men and 3 women were affected (age 71 years; range, 59.8-75.5 years). Critically ill patients with sclerosing cholangitis required vasoconstrictors and inotropes longer than control patients (norepinephrine 356.5 hours [264.5-621] vs 68 hours [15-132.5], P = .003; enoximone 177 hours [124.3-249.5] vs 48.5 hours [12-81 hours], P < .001, respectively). Critically ill patients with sclerosing cholangitis had longer intubation time (628.5 hours [377.3-883] vs 25 hours [9.8-117.5]; P < .001) and more surgical revisions (3 [2.5-6] vs 1 [0-2], P = .003) than the matching group. Bilirubin (23.3 mg/dL [14.4-32.9] vs 1 mg/dL [0.6-2.7]; P < .001), gamma-glutamyltransferase (1082.3 U/L [259.5-2265.7] vs 53.8 U/L [35.1-146]; P < .001), and alkaline phosphatase (751.5 U/L [372-1722.3] vs 80.5 U/L [53.3-122]; P < .001) were higher in critically ill patients with sclerosing cholangitis. One critically ill patient with sclerosing cholangitis underwent successful liver transplantation. A total of 11 patients sclerosing cholangitis died (92%) versus 12 patients (33%, P < .001) in the control group. CONCLUSIONS: Sclerosing cholangitis in critically ill patients is a fatal complication in patients undergoing cardiac surgery who have a complicated postoperative course with prolonged vasoconstrictor, inotropic, and respiratory therapy, or who require frequent surgical revisions. Liver transplantation remains the only curative option but is often precluded by the age and critical state of patients undergoing cardiac surgery.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Schade I, Radakovic D, Hoffmann J, et al. Secondary sclerosing cholangitis in cardiac surgical patients: A complication with a dismal prognosis. J Thorac Cardiovasc Surg. 2017. PMID: 28554673. doi:10.1016/j.jtcvs.2017.04.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。